ホーム › 頭頸部扁平上皮癌 › ケンタッキー州 › Louisville
Louisville、KYにおける頭頸部扁平上皮癌の臨床試験
Louisvilleとその周辺地域（約30マイル以内）の拠点で、頭頸部扁平上皮癌に関する11件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
被験者募集中第2/3相
- Site#0111, Louisville
- Site#0115, Louisville
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
被験者募集中第2相
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
被験者募集中第1相
- Norton Cancer Institute, Louisville
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
被験者募集中第2相
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
被験者募集中第2相
- Norton Cancer Institute, Louisville
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
被験者募集中第2相
- Baptist Health Floyd, New Albany · 4マイル先
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
被験者募集中第3相
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
被験者募集中第1/2相
- Norton Cancer Institute, Louisville
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
被験者募集中第1/2相
- Norton Cancer Institue Downtown, Louisville
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
被験者募集中第1相
- Norton Cancer Institute /ID# 248903, Louisville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 115, Louisville
他の都市における頭頸部扁平上皮癌の試験
- Houston, TX47件の研究
- Los Angeles, CA42件の研究
- Boston, MA40件の研究
- New York City, NY39件の研究
- Nashville, TN39件の研究
- St. Louis, MO28件の研究
- Arlington, VA26件の研究
- Philadelphia, PA26件の研究
- Chicago, IL26件の研究
- Atlanta, GA24件の研究
- San Antonio, TX22件の研究
- New Haven, CT22件の研究
Louisvilleにおける他の研究
- 非小細胞肺癌22件の研究
- 肥満症17件の研究
- 過体重15件の研究
- がん（全種類）14件の研究
- 心不全13件の研究
- 急性骨髄性白血病12件の研究
- 多発性骨髄腫12件の研究
- 卵巣がん12件の研究
- 乳がん11件の研究
- 肺がん11件の研究
- 悪性黒色腫10件の研究
- 前立腺がん10件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。